Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations
GBM|Glioblastoma|Brain Tumor|Brain Tumor, Recurrent
DRUG: Abemaciclib|DRUG: Bevacizumab
Number of participants with adverse event, Assess safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations.

NCI Common terminology criteria for adverse events (CTCAE v.5) will be used to assess the adverse events., upto 2 years after study treatment
Median Overall Survival, Median OS of the study patients from time of study entry until death or lost to follow-up., upto 2 years after study treatment|Median Progression Free Survival, Median PFS of the study patients from time of study entry until progression as determined by the Response Assessment in Neuro-Oncology (RANO) criteria \[30\]., upto 2 years after study treatment
Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations